[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"59th Medical Wing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,66,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100584668","evaluation-of-a-device-to-reduce-motion-sickness-and-spatial-disorientation-100584668",false,"NCT06892340","Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation","A Non-Invasive, Non-Sedating Device to Mitigate Motion Sickness and Spatial Disorientation","* Inclusion Criteria:\n\n  1. Healthy males and non-pregnant females between the ages of 18-50 who do not experience symptoms of motion sickness.\n  2. Participants who are English speaking.\n  3. Participants who are able to read and understand study procedures in order to provide informed consent.\n* Exclusion Criteria:\n\n  1. Females who are pregnant\n  2. Cardiac pathology (congestive heart failure, history of myocardial infarction, cardiac stent placement, pacemaker placement, heart surgery)\n  3. Hypertension requiring daily medication\n  4. Active vestibular disease to include Meniere's disease, migraine associated vertigo, benign paroxysmal positional vertigo, labyrinthitis\n  5. Neck pain or spinal pathology\n  6. Medications impacting cardiac, vestibular, or neurologic function\n  7. Recently ill or hospitalized within 30 days\n  8. Pilots and individuals formally desensitized to motion sickness\n  9. Use of vestibular suppressing medications or drugs within 24 hours of the study (antihistamines, histamine-1 receptor agonists, benzodiazepines, anticholinergics, dopamine receptor agonists, alcohol, marijuana, tobacco, opiates)\n  10. Participant has a history of epileptic seizures\n  11. Participant has a history of neurological diseases or traumatic brain injury\n  12. Abnormal vital signs obtained during pre-experimentation phase:\n* Heart Rate \\>100 or \\\u003C50\n* Systolic blood pressure \\>150 or \\\u003C90\n* Respiratory rate \\>24 or \\\u003C8 13. Participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators 14. Participant has abnormal ear anatomy or ear infection present 15. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial",true,"ALL","18 Years","50 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this research study is to learn how a wearable nerve stimulation device, the Spark Biomedical's Sparrow Ascent System™, impacts the development of spatial disorientation and\u002For motion sickness in a healthy population.\n\nSpatial disorientation is when there is a \"mismatch\" between where a person is, and where the sense organs in their body tell them where they are. These sense organs include the inner ear (the vestibular system), the eyes (the visual system), the sense of where one's legs, back, and neck are (proprioceptive system), and one's higher thinking (cognitive centers). If spatial disorientation is severe or occurs in motion-naïve individuals, spatial disorientation can lead to motion sickness.\n\nThe Sparrow Ascent System™ is a wearable, battery-operated transcutaneous auricular (ear) neurostimulation (tAN) device. This means that it uses electrical pulses to stimulate branches of nerves on and\u002For around the ear, specifically the \"vagus\" and \"trigeminal\" nerves. These nerves are also responsible for your sensation of nausea and your heart rate (vagus nerve), as well as headaches (trigeminal nerve). The Sparrow System utilizes a flexible earpiece with embedded hydrogel electrodes that stick to the skin, the earpiece is disposable after use. This device is already Food and Drug Administration (FDA) approved for use in humans and is safely used for control of symptoms in a variety of other medical conditions, such as opioid withdrawal and acute stress reaction. In this study, we will determine if the Sparrow Ascent System™ impacts the development of spatial disorientation or motion sickness.",[28],"Motion Sickness",[28,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Simulator Sickness","Trigeminal innervation","Transcutaneous auricular neurostimulation","Sparrow Ascent","Neuromodulation","Simulator adaption syndrome","Transcutaneous vagus nerve stimulation","Auricle","Mild electrical stimulation","Cranial nerves","Occipital nerves","Cymba Concha","Afferent sensory innervation","Vagus Nerve","Auriculotemporal nerve","Trigeminal nerve","Auricular nerve","Cranial nerve V","Cranial nerve VII","Cranial nerve IX","Cranial nerve X","Non-invasive","Non-sedating","RECRUITING","2025-08-12",{"date":56,"type":57},"2025-08-15","ACTUAL",{"date":59,"type":57},"2025-02-21",{"date":61,"type":22},"2025-10-31",{"name":63,"class":64},"59th Medical Wing","FED",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":16,"sex":17,"minAge":73,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":65},"100442129","contoura-vs-wfo-ablation-prk--lasik-100442129","NCT05037370","CONTOURA vs WFO Ablation PRK & LASIK","Topography-guided vs. Wavefront Optimized Corneal Refractive Surgery: A Prospective Contralateral Randomized Double-masked Study","Inclusion Criteria:\n\n* Meet requirements for PRK or LASIK i.e., Stable \\\u003C= .5 D change MRSE)\n* DOD beneficiaries age 21-50 years\n* Local pts (w\u002Fi 60 mi) who will be in the area for at least 6 months post surgery\n* Willing to complete all required follow-up visits\n\nExclusion Criteria:\n\n* No meeting requirements for PRK or LASIK\n* Desiring monovision treatment\n* Anisometropia \\>2D spherical equivalent\n* Prior ocular surgeries \u002F trauma \u002F problem\n* History of dry eyes\n* Hyperopia\n* Mixed astigmatism\n* Inability to capture VARIO topolyzer scans\n* Pregnant (or who plans to be within 6 months after surgery)\n* Breastfeeding any time during the study\n* History of herpetic disease","21 Years",{"count":75,"type":22},400,[25],"This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.",[79],"Refractive Surgery",[81,82,83,84],"Photorefractive Keratectomy (PRK)","Laser-assisted in situ Keratomileusis (LASIK)","Wave-Front Optimized (WFO)","Topography guided ablation","2025-08-11",{"date":87,"type":57},"2025-08-14",{"date":89,"type":57},"2021-04-22",{"date":91,"type":22},"2026-12-31",{"name":63,"class":64},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":65},"100504138","nanodropper-use-in-primary-open-angle-glaucoma-patients-a-non-inferiority-trial-100504138","NCT05844384","Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial","Inclusion Criteria:\n\n* POAG\u002FOHTN patients above the age of 18 years.\n* On a maximum of 2 IOP lowering medications.\n* Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.\n\nExclusion Criteria:\n\n* Glaucoma not of the POAG or OHTN variety or other retinal diseases.\n* Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).\n* Using more than 2 IOP-lowering medications.\n* IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.",{"count":100,"type":22},30,[25],"This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.",[104,105],"Ocular Hypertension","Primary Open Angle Glaucoma",[107,105,108,104],"Nanodropper","Microdrops","2023-05-03",{"date":111,"type":57},"2023-05-06",{"date":113,"type":57},"2022-03-17",{"date":115,"type":22},"2024-03-17",{"name":63,"class":64},""]